About PharmaMar
PharmaMar is a publicly listed company based in Colmenar Viejo (Spain) founded in 1986. Marine-derived antitumor drugs are discovered and developed by PharmaMar. Its chief executive, as recorded, is José Maria Fernandez. Its website pharmamar.com draws about 13 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 1986 and based in Colmenar Viejo, Spain, PharmaMar operates in the pharmaceutical sector focused on oncology. Antitumor compounds from marine sources are researched, developed, and commercialized, including YONDELIS (trabectedin) approved in Europe for soft tissue sarcoma and ovarian cancer. Three additional programs are in clinical stagesPM1183, plitidepsin, and PM184targeting various solid and hematological cancers through mechanisms like RNA polymerase II inhibition, oxidative stress induction, and tubulin polymerization disruption.
- Headquarters Colmenar Viejo, Spain
- Stage Public
- SectorsHealthcare
- Website pharmamar.com
- Social LinkedIn X
- Legal Name Pharma Mar Sa
- Annual Revenue$260.13 M (USD)26.61as on Dec 31, 2025
- Net Profit$88.11 M (USD)187.03as on Dec 31, 2025
- EBITDA$56.75 M (USD)417.39as on Dec 31, 2025
- Latest Funding Round$409.92K (USD), Grant
Jun 2021
- Investors
Funding Insights of PharmaMar
- Total Rounds 2
- Last Round Grant — $409,921
- First Round $268,629
(Apr 2015)
- Investors Count 1
All 2 funding rounds of PharmaMar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $409,921 | Grant | – | – | |
| Apr 2015 | $268,629 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in PharmaMar
PharmaMar has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for PharmaMar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PharmaMar
42 people are tracked at PharmaMar (29 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
José Maria Fernandez | Chairman & CEO | Leadership |
Kostas Vasilakis | International Markets Lead & Country Head Switzerland | Leadership |
María Luisa de Francia Caballero | Chief Financial Officer | Leadership |
Elisa Borrego | Director, Public Affairs | Leadership |
Heiner Pieper | VP, Business Development & Licensing | Leadership |
Belén Sopesén Veramendi | Director, Virology Business Unit | Leadership |
Lara Vadillo | Comunication Director | Leadership |
Sandra Llamera Sánchez | Global Compliance Head | Leadership |
Pascal Besman | Chief Operating Officer | Leadership |
María José Arce-Tomas | Global Head of Regulatory Affairs | Leadership |
Elena Calleja Crespo | Director, Finance Oncology Business Unit | Leadership |
Luis Rupérez Cuenca | Director, Human Resources & IT | Leadership |
D. José María Fernández Sousa-Faro | President, CEO & Chairman | Leadership |
José María Jimeno | VP, Global Head Virus & Inflammation | Leadership |
María Lisa Basile | Global Commercial Head of Oncology | Leadership |
Carmen Cuevas Marchante | VP, Reseach & Development | Leadership |
Diego López Mendoza | Head, Virology Business Unit | Leadership |
María Concepción Sanz | Legal Director, Business | Leadership |
Hervé Ghislain Dhellot | Qppv/global Pharmacovigilance Head | Leadership |
Carmen Eibe | Director, Project Coordination | Leadership |
22 more people are available in the full profile.
Complete people profiles for PharmaMar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of PharmaMar
PharmaMar is a publicly listed company on the BME with ticker symbol PHM in Spain, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Nov 2015
- Listed onBME: PHM
- Listed entityPharma Mar SA
- Exchange sectorHealth technology
- ISINES0169501022
- Share price66.50 EUR (+0.08% on the day) · 2026-10-14
- Market capitalisation1,179,662,478.00 EUR
- Price to earnings20.7
- EPS (diluted, trailing year)3.21 EUR
- Dividend yield1.19%
- Volume (last session)3,000
Financials of PharmaMar
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 221.4M EUR | 75.0M EUR | 48.3M EUR |
| 2024 | 174.8M EUR | 26.1M EUR | 9.3M EUR |
| 2023 | 158.2M EUR | 1.1M EUR | 406,000 EUR |
| 2022 | 196.3M EUR | 49.4M EUR | 48.2M EUR |
| 2021 | 229.8M EUR | 92.9M EUR | 96.0M EUR |
Detailed financial statements for PharmaMar
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of PharmaMar
4 dated milestones of PharmaMar across 35 years, from founding to its latest funding, stage changes and deals.
- Founded PharmaMar is founded.
- Funding First funding round of $269K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $410K.
Web traffic of PharmaMar
The website of PharmaMar (pharmamar.com) receives about 13.4K visits a month.
- Monthly visits13.4K
▼ 5.5% vs previous month
Websites whose visitors overlap most with PharmaMar. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| eusapharma.com | 100% | View details | |||
| novartis.com | 100% | 948.8K | #58,822 | View details | |
| taiho.co.jp | 100% | #293,478 | View details | ||
roche.pt | roche.pt | 66% | #1,714,101 | – | |
msd.pt | msd.pt | 66% | #5,601,229 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for PharmaMar
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmamar
Complete news archive for PharmaMar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmaMar
PharmaMar was founded in 1986 and raised its 1st funding round 29 years after it was founded.
PharmaMar is headquartered in Colmenar Viejo, Spain. It is registered at Colmenar Viejo, Comunidad De Madrid, Spain.
José Maria Fernandez is the CEO of PharmaMar, as recorded in our data.
Annual revenue of PharmaMar is $260.13M as on Dec 31, 2025.
Founded in 1986 and based in Colmenar Viejo, Spain, PharmaMar operates in the pharmaceutical sector focused on oncology. Antitumor compounds from marine sources are researched, developed, and commercialized, including YONDELIS (trabectedin) approved in Europe for soft tissue sarcoma and ovarian cancer. Three additional programs are in clinical stagesPM1183, plitidepsin, and PM184targeting various solid and hematological cancers through mechanisms like RNA polymerase II inhibition, oxidative stress induction, and tubulin polymerization disruption.
Yes, PharmaMar is publicly traded on BME under the ticker symbol PHM.
PharmaMar has 1 investor. Key investors include European Union.